PARADIGM-HF

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instance_of gptkb:legal_case
gptkbp:allows specific population studied
short follow-up in some cases
gptkbp:analysis statistical analysis
gptkbp:clinical_trial highly significant results
NC T01950758
gptkbp:collaborations various academic institutions
gptkbp:collection clinical assessments
gptkbp:duration up to 36 months
gptkbp:events median 27 months
gptkbp:field_of_study cardiology
gptkbp:focus heart failure
gptkbp:future_plans long-term effects of treatment
comparative effectiveness studies
https://www.w3.org/2000/01/rdf-schema#label PARADIGM-HF
gptkbp:impact influenced future studies
changed heart failure treatment guidelines
gptkbp:is_compared_to gptkb:enalapril
gptkbp:is_protected_by gptkb:sacubitril/valsartan
gptkbp:is_studied_in double-blind
gptkbp:is_tested_for Phase III
gptkbp:launch_date 2010-12-01
gptkbp:location multiple countries
gptkbp:notable_work improved exercise capacity
better symptom control
sacubitril/valsartan improved quality of life
sacubitril/valsartan reduced cardiovascular death
significant reduction in mortality
sacubitril/valsartan reduced heart failure hospitalizations
gptkbp:participants hospitalization for heart failure
change in NT-pro BNP levels
gptkbp:population chronic heart failure patients
gptkbp:publishes gptkb:New_England_Journal_of_Medicine
gptkbp:receives_funding_from gptkb:Company
gptkbp:regulatory_compliance FDA approved
EMA approved
gptkbp:research randomized controlled trial
multicenter trial
sacubitril/valsartan was superior to enalapril
gptkbp:result gptkb:2014
gptkbp:side_effect renal impairment
hypotension
hyperkalemia
gptkbp:sponsor gptkb:Novartis
gptkbp:student_enrollment adults with heart failure
approximately 8,442 participants
gptkbp:treatment reduced hospital readmissions
improved overall survival
gptkbp:year 2014-12-01
gptkbp:bfsParent gptkb:Entresto
gptkbp:bfsLayer 4